Standard BioTools Stock (NASDAQ:LAB), Trade Ideas

Standard BioTools

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Long Ideas

News

Penny Stocks

Small Cap

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ETST

The Dow Jones index closed higher by around 75 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Quantum-Si And 2 Other Penny Stocks Insiders Are Buying

Biotech

Health Care

Initiation

Analyst Ratings

Movers

General

KeyBanc Capital Markets initiated coverage on Standard BioTools Inc (NASDAQ: LAB) with an Overweight rating and a 

Standard BioTools Get a Buy Rating, Analyst Cites Unique Technology, Management and Board

Intraday Update

ABCM

AREB

AVXL

AXSM

BNRG

BPTS

CHEK

CINC

CNTG

COSM

CYXT

DADA

DBGI

DKNG

Euda Health Holdings Limited - Ordinary Shares

EUDA

FLNC

GRND

GSUN

HAIN

HLBZ

KPLT

Kintara Therapeutics, Inc. - Common Stock

KTRA

LGHL

MICS

NAMS

NAOV

ONCS

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PHGE

PKBO

PRME

PRSO

PSNY

RCRT

RNAZ

SatixFy Communications Ltd. Ordinary Share

SATX

SCLX

SNMP

TALK

TBLA

TCBP

TCDA

TRKA

UNVR

XPON

Gainers


	Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo.


Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday&#39;s Mid-Day Session

Standard BioTools Inc

Direxion Daily S&P Biotech Bear 3X Shares

LABORATORIOS FARMACEUTICO by LABORATORIOS FARMACEUTICOS ROVI SA

Laboratorios Farmaceuticos Rovi SA

Landos Biopharma Inc

LABS Group

Direxion Daily S&P Biotech Bull 3X Shares

METASPHERE LABS INC by METASPHERE LABS INC.

Metasphere Labs Inc

Ratings for CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CVB Financial and provided 12-month price targets. The average target is $19.0, accompanied by a high estimate of $20.00 and a low estimate of $18.00. This current average has decreased by 5.0% from the previous average price target of $20.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1714147235_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive CVB Financial is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Andrew Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Erik Zwick</td>
<td>Hovde Group</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVB Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CVB Financial compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CVB Financial's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CVB Financial's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVBF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CVB Financial analyst ratings.</a>
<h2>Unveiling the Story Behind CVB Financial</h2>
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
<h3>Financial Insights: CVB Financial</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, CVB Financial faced challenges, resulting in a decline of approximately -7.48% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: CVB Financial's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 34.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.39%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): CVB Financial's ROA excels beyond industry benchmarks, reaching 0.3%. This signifies efficient management of assets and strong financial health.
Debt Management: CVB Financial's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.0, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVBF

Assessing CVB Financial: Insights From 4 Financial Analysts

Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) has outperformed the market over the past 5 years by 29.16% on an annualized basis producing an average annual return of 40.75%. Currently, Ares Management has a market capitalization of $26.03 billion. 
Buying $1000 In ARES: If an investor had bought $1000 of ARES stock 5 years ago, it would be worth $5,530.92 today based on a price of $133.73 for ARES at the time of writing.
<h3>Ares Management's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714147228_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,500 Today

RBC Capital analyst Kutgun Maral maintains T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) with a Outperform and raises the price target from $184 to $188.

Price Target

TMUS

RBC Capital Maintains Outperform on T-Mobile US, Raises Price Target to $188

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 15 years by 4.91% on an annualized basis producing an average annual return of 17.08%. Currently, Autodesk has a market capitalization of $46.65 billion. 
Buying $100 In ADSK: If an investor had bought $100 of ADSK stock 15 years ago, it would be worth $1,110.90 today based on a price of $218.07 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714147222_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,100 Today

In the last three months, 5 analysts have published ratings on KKR Real Estate Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $10.95, along with a high estimate of $13.00 and a low estimate of $9.75. A 8.75% drop is evident in the current average compared to the previous average price target of $12.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1714147217_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of KKR Real Estate Finance among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jade Rahmani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$9.75</td>
<td>$10.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$11.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.50</td>
<td>$12.00</td>
</tr>
<tr>
<td>Steven Delaney</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$14.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to KKR Real Estate Finance. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of KKR Real Estate Finance compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of KKR Real Estate Finance's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of KKR Real Estate Finance's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KREF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on KKR Real Estate Finance analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About KKR Real Estate Finance</h2>
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
<h3>KKR Real Estate Finance: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining KKR Real Estate Finance's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -12.03% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: KKR Real Estate Finance's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -22.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.63%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): KKR Real Estate Finance's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.12%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a high debt-to-equity ratio of 4.2, KKR Real Estate Finance faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KREF

5 Analysts Have This To Say About KKR Real Estate Finance

Truist Securities analyst Brandon King maintains Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) with a Hold and raises the price target from $30 to $32.

TRMK

Truist Securities Maintains Hold on Trustmark, Raises Price Target to $32

RBC Capital analyst Brad Erickson maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Sector Perform and raises the price target from $13 to $16.

SNAP

RBC Capital Maintains Sector Perform on Snap, Raises Price Target to $16

Truist Securities analyst Scot Ciccarelli maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Buy and raises the price target from $277 to $289.

TSCO

Truist Securities Maintains Buy on Tractor Supply, Raises Price Target to $289

Newell Brands Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) shares are&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38455689/newell-brands-announces-first-quarter-2024-results" rel="noreferrer noopener">trading higher on Friday.</a>
The company&#8217;s first-quarter&nbsp;adjusted earnings per share were at the break-even point, compared with&nbsp;the&nbsp;analyst consensus estimate of a 7-cent loss. Quarterly revenues of $1.653 billion&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beat the street view of $1.644 billion.</a>
Net sales slumped 8.4% compared with the prior year period, while the core sales declined by 4.7%.
Normalized gross margin increased to 31.2% compared with 27.1% in the prior year period. Normalized operating margin increased to 4.6% compared with 2.4% in the prior year.
Operating cash flow increased by $109 million to $32 million compared with the prior year&nbsp;period.
At the end of the first quarter, Newell Brands had debt outstanding of $5.0 billion and cash and cash equivalents of $372 million.
In January 2024, the company announced an organizational realignment, which&nbsp;is expected&nbsp;to strengthen the company&#8217;s front-end commercial capabilities.
Once the organizational design changes&nbsp;are fully executed, the company expects to realize annualized pretax savings&nbsp;in the range&nbsp;of $65 million to $90 million, net of reinvestment, with $55 million to $70 million expected in 2024.
During the first quarter of 2024, the company incurred restructuring and related charges of $22 million related to the plan.
Outlook:&nbsp;Newell Brands forecasts a second-quarter sales decline of 9%-7%, with core sales&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">to fall between 6% and 4%</a>. The company projects second-quarter normalized EPS of $0.18 to $0.21 versus analyst consensus of $0.25. The company affirmed&nbsp;its FY24 sales outlook for a decline of 8% to 5%, with normalized EPS of $0.52 to $0.62 versus the $0.57 estimate.
Price Action: NWL shares are trading higher by 10.7% to $7.68 at last check Friday.
Image via company

Earnings

Equities

Guidance

Why Newell Brands Shares Are Gaining Friday

Truist Securities analyst Jasper Bibb maintains Strategic Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) with a Buy and raises the price target from $125 to $145.

STRA

Truist Securities Maintains Buy on Strategic Education, Raises Price Target to $145

Eurozone

Global

VRTX

Vertex Announces European Commission Approval For Kalydeco To Treat Infants With Cystic Fibrosis Ages 1 Month And Older

Truist Securities analyst Youssef Squali maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Hold and raises the price target from $12 to $16.

Truist Securities Maintains Hold on Snap, Raises Price Target to $16

RBC Capital analyst Brian Abrahams maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Perform and lowers the price target from $26 to $15.

SAGE

RBC Capital Maintains Sector Perform on Sage Therapeutics, Lowers Price Target to $15

Chevron CEO Says Co Estimates Arbitration Will Conclude In Q4, Consistent With Exxon's Timeline

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $22 to $18.

Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $18

Chevron CEO Says Co Has Not Received Timing Schedule From Tribunal Over Arbitration Process

GOOG

GOOGL

Google Invests $3B In Data Center Campuses In Virginia, Indiana

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Sector Perform and raises the price target from $187 to $200.

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $200

Truist Securities analyst Jamie Cook maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Hold and raises the price target from $121 to $132.

Truist Securities Maintains Hold on Oshkosh, Raises Price Target to $132

WIIM

SNOW

Snowflake shares are trading higher after Microsoft reported strong growth in Azure.

Standard BioTools GAAP EPS of -$0.25 misses by $0.01, revenue of $28.19M beats by $3.29M

The latest update is out from Standard BioTools (LAB). Standard BioTools Inc. presents an optimistic 2024 outlook and relevant company details, whi...

Standard BioTools Projects Positive Outlook for 2024

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

Standard Biotools exchanges all outstanding Series B convertible preferred stock for common stock

Standard BioTools (LAB) has issued an announcement. Standard BioTools Inc. has successfully conducted a strategic stock exchange with major investo...

Standard BioTools Streamlines Structure and Strengthens Governance

Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader

Standard Biotools enters strategic engagement with Bristol Myers for expanded use of Somascan platform

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bausch Health Companies (BHC – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Standard BioTools (LAB)

The latest announcement is out from Standard BioTools (LAB). Standard BioTools Inc. is streamlining its workforce by 10% and reshuffling senior man...

Standard BioTools: Workforce Cut and Management Reshuffle Post-Merger

Standard Biotools announces operational restructuring plan including headcount reduction

AKYA

CTKB

RVTY

TCGGY

TCHBF

TECH

Press Releases

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Standard BioTools to Participate in Upcoming Investor Conferences

Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging

Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals

ChromaDex

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share